Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Endocrinol Metab. 2012 Nov;23(11):552-9. doi: 10.1016/j.tem.2012.06.009. Epub 2012 Jul 31.

Genetically-defined metabolic reprogramming in cancer.

Author information

1
Children's Research Institute, Department of Pediatrics and McDermott Center for Human Growth and Development, University of Texas - Southwestern Medical Center, Dallas, TX 75390-8502, USA.

Abstract

Oncogenes and tumor suppressors regulate cell metabolism. Evidence demonstrates that tumorigenic mutations in these genes tend to orchestrate metabolic activity into a platform that promotes cell survival, growth, and proliferation. Recent work has shown that some metabolic enzymes are also mutated in cancer, and that these mutations may influence malignancy directly. Thus, these enzymes seem to function as oncogenes and tumor suppressors, and would appear to be compelling targets for therapeutic intervention. Here, we review several enzymes mutated in cancer - phosphoglycerate dehydrogenase, isocitrate dehydrogenases 1 and 2, succinate dehydrogenase, and fumarate hydratase - and discuss exciting new work that has begun to pull back the curtain on how mutations in these enzymes influence tumorigenesis.

PMID:
22858391
PMCID:
PMC3466334
DOI:
10.1016/j.tem.2012.06.009
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center